Von Willebrand Disease (VWD)
Part 2: NHLBI Diagnosis Guidelines

Sensitivity and Specificity of the Screening Panel

June 2011

By using this criteria, we screened the same 492 samples; we can catch 100% congential VWD samples and 83% of acquired VWF abnormalities due to subtle losses of highest molecular weight multimers. The specificity is 92% which can be translated into a 92% reduction of VWF ristocetin cofactor activity testing volume of the potentially normal samples.

< Previous Slide

Sensitivity and Specificity of the Screening Panel

Next Slide >

 

Jump to section:

• Introduction
• Objectives
• History of VWF Ristocetin Cofactor Activity (VWF:RCo) Assay
• Problems with VWF:RCo Assay
• Summary of External Quality Assessment of VWF:RCo
• von Willebrand Disease(VWD) Diagnostic Error Rates Due to Erroneous VWF:RCo Results⁵
• VWF:RCo/Ag Ratio is Insensitive for Aquired von Willebrand Abnormalities (AVWA)
• VWF:RCo is Inadequate for Detecting AVW Abnormality
• The New Automated VWF Activity by Latex-Immunoturbidity Assay (VWF:Lx)
• VWF Activity Assay by an A1 Domain Conformation-Sensitive Antibody⁶
• Performance Characteristics of VWF:Lx
• VWF:Lx and VWF:RCo Method Comparison
• VWF:Lx and VWF:RCo Bias Analysis
• Sample Categorization
• Comparison of VWF:Lx/Ag and VWF:RCo/Ag Ratios
• VWF:Lx and VWF:RCo Errors
• Severe Type 1 vs 2M⁷
• VWF:Lx and RCo Errors
• VWF:Lx/Ag is Sensitive to AVWA with Subtle Loss of Highest HMWM
• ROC Analysis of VWF:Lx/Ag and VWF:RCo/Ag for Detecting AVWA with Loss of HMWMs
• VWF:Lx/Ag vs VWF:RCo/Ag Ratios
• VWF Laboratory Testing Strategy
• Sensitivity and Specificity of the Screening Panel
• von Willebrand Disease Profile
• von Willebrand Disease Profile
• von Willebrand Disease Profile
• von Willebrand Disease Profile
• Limitations of VWF:Lx
• Summary
• References
• Questions?